All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Fixed-duration ibrutinib + venetoclax receives EC approval as first-line treatment for chronic lymphocytic leukemia

Aug 5, 2022
Learning objective: After reading this article, learners will be able to cite a new clinical development in CLL.

Bookmark this article

On August 4, 2022, it was announced that the European Commission (EC) had granted approval to ibrutinib, a Bruton’s tyrosine kinase inhibitor, in combination with venetoclax, a BCL-2 inhibitor, as an oral fixed-duration regimen for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL). The approval is based on key data obtained from the phase III GLOW and phase II CAPTIVATE clinical trials (NCT03462719; NCT02910583).1

The GLOW trial reported a superior progression-free survival for ibrutinib + venetoclax over chlorambucil-obinutuzumab in elderly and unfit adult patients with CLL. The CAPTIVATE trial showed that treatment with ibrutinib + venetoclax led to deep and durable responses in patients ≤70 years of age with previously untreated CLL.

  1. Business Wire. European Commission approves Imbruvica® (ibrutinib) in a fixed-duration combination regimen for adult patients with previously untreated chronic lymphocytic leukaemia (CLL). Published Aug 4, 2022. Accessed Aug 4, 2022.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you


Subscribe to get the best content related to lymphoma & CLL delivered to your inbox